Previous close | 143.05 |
Open | 142.64 |
Bid | 144.34 x 1100 |
Ask | 144.60 x 900 |
Day's range | 141.83 - 144.97 |
52-week range | 117.08 - 189.07 |
Volume | |
Avg. volume | 966,134 |
Market cap | 34.905B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 3.39 |
EPS (TTM) | 42.47 |
Earnings date | 27 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 02 Jun 2022 |
1y target est | 208.90 |
Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline The investment of approximately €40 million is part of a long-term development plan for BioNTech’s manufacturing site in Marburg German Chancellor Olaf Scholz is visiting the facility together with BioNTech co-founders
Today is shaping up negative for BioNTech SE ( NASDAQ:BNTX ) shareholders, with the analysts delivering a substantial...
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.